Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients

Ma, Xiao; Zhang, Ziran; Chen, Xiaoling; Zhang, Jie; Nie, Jing; Ling, Da; Hu, Weiheng; Tian, Guangming; Wu, Di; Han, Jindi; Han, Shiyu; Long, Jieran; Wang, Yang; Fang, Jian

doi:10.1111/1759-7714.13846

Cited by 24 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to males, females could benefit from chemotherapy, and had longer OS and PFS which coincided with the published studies [24]. Although ECOG was significantly against both OS and PFS in previous studies [25], because of the excellent performance status of LS patients, it did not relate to OS in ours. Additionally, our results indicated that the treatment-related factors of chemotherapy cycles, radiotherapy, and PCI were significantly correlated to the prognosis of LS-SCLC.…”

Section: Discussionsupporting

confidence: 85%

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

Background Lung immune prognostic index (LIPI) is a prognostic marker of extensive-stage small cell lung cancer (ES-SCLC) patients received immunotherapy or chemotherapy. However, its ability in limited-stage SCLC (LS-SCLC) should be evaluated extensively. Methods We retrospectively enrolled 497 patients diagnosed as LS-SCLC between 2015 and 2018, and clinical data included pretreatment lactate dehydrogenase (LDH), white blood cell count, and absolute neutrophil count levels were collected. According to the LIPI scores, the patients were stratified into low-risk (0 points) and high-risk (1–2 points). The correlations between LIPI and overall survival (OS) or progression-free survival (PFS) were analyzed by the Cox regression. Additionally, the propensity score matching (PSM) and inverse probability of treatment weight (IPTW) methods were used to reduce the selection and confounding bias. A nomogram was constructed using on multivariable Cox model. Results Two hundred fifty and 247 patients were in the LIPI high-risk group and low-risk group, and their median OS was 14.67 months (95% CI: 12.30–16.85) and 20.53 months (95% CI: 17.67–23.39), respectively. In the statistical analysis, High-risk LIPI was significantly against worse OS (HR = 1.377, 95%CI:1.114–1.702) and poor PFS (HR = 1.338, 95%CI:1.1–1.626), and the result was similar after matching and compensating with the PSM or IPTW method. A novel nomogram based on LIPI has a decent level of predictive power. Conclusion LIPI stratification was a significant factor against OS or PFS of LS-SCLC patients.

show abstract

Section: Discussionsupporting

confidence: 85%

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These comprehensive biomarkers are developed based on clinical and laboratory parameters, the number of which varied between two and seven. ECOG PS and LDH have been widely accepted as prognostic factors, and both are the parameters most frequently concluded in the scoring system (30,31). PILE is a prognostic candidate score consisting of PIV, LDH, and ECOG PS, which was developed by a simple 0/1 scoring system (for PIV < median = 0, ≥median = 1; for LDH ≤ULN = 0, >ULN = 1; for ECOG PS <2 = 0, ≥2 = 1).…”

Section: Discussionmentioning

confidence: 99%

“…Considering that most clinical trials excluded patients with ECOG PS ≥2, the dramatic underrepresentation of patients with ECOG PS ≥2 makes it difficult to ascertain the real benefit of anti-PD-1/L1 inhibitor in this patient population (27). Moreover, the majority of SCLC patients already have ES disease when they were first diagnosed, in which there were more patients of ECOG PS 2-3 (30). Hence, we decided ECOG PS = 2 as a cutoff value, instead of ECOG PS = 1 reported in the previous literature (24).…”

Section: Discussionmentioning

confidence: 99%

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

et al. 2021

View full text Add to dashboard Cite

ObjectivesThe objective of this study is to evaluate whether PIV (Pan-Immune-Inflammation Value) and PILE [a score derived from PIV, lactate dehydrogenase (LDH), and Eastern Cooperative Oncology Group Performance Status (ECOG PS)] can predict clinical outcome of anti-PD-1/PD-L1 inhibitor combined with chemotherapy in patients with extensive-stage (ES) small cell lung cancer (SCLC).MethodsA total of 53 patients with ES-SCLC in the control group of clinical trial (NCT03041311) were included in this study. PIV was calculated as follows: (neutrophil count × platelet count × monocyte count)/lymphocyte count. The PILE scores were composited based on PIV, LDH levels, and ECOG PS. The Kaplan–Meier method and Cox hazards regression models were used for survival analyses. Moreover, the predictive ability of PIV and PILE was validated in an independent real-world group consisting of 84 patients.ResultsPatients in the low PIV group (PIV < median) had longer progression-free survival (PFS) and overall survival (OS) than those in the high PIV group (PIV ≥ median), along with the HR, which was 2.157 and 2.359, respectively (PFS HR 95% CI: 1.181–3.940, p = 0.012; OS HR 95% CI: 1.168–4.762, p = 0.020). High PILE score was observed relating to worse treatment efficacy (disease control rate (DCR): 84.21% vs. 100%, p = 0.047; durable clinical benefit (DCB) rate: 10% vs. 48.5%, p = 0.060) and poor clinical outcome (median PFS: 4.75 vs. 5.53 m, p = 0.043; median OS: 7.13 vs. 15.93 m, p = 0.002). Similar results were obtained about the predictive and prognostic abilities of PIV and PILE scores in the validation group.ConclusionsHigh PIV and high PILE were correlated with worse clinical outcomes in ES-SCLC patients treated with anti-PD-1/PD-L1 inhibitor combined with chemotherapy, reflecting that PIV and PILE might be useful to identify patients unlikely to benefit from anti-PD-1/PD-L1 therapy.

show abstract

“…Another even more recent and large real‐world study on both LS‐ and ES‐SCLC found that ECOG PS 0–1, response to primary systemic treatment, aggressive RT, and three or more lines of CT were predictive of better OS in the whole group. 21 In the multivariable analysis, more advanced age was not an unfavorable prognostic factor. Even the presence of comorbidities did not have an impact on survival.…”

Section: Discussionmentioning

confidence: 85%

Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade

et al. 2022

View full text Add to dashboard Cite

Background Potential relationships with the prognosis of patients with extensive‐stage non‐small cell lung cancer (ES‐SCLC) have been investigated without valid results. Methods A retrospective analysis of real‐world data of consecutive patients with ES‐SCLC admitted to our Medical Thoracic Oncology Unit was carried out from 2010 to 2020, focusing on identification of prognostic factors. Kaplan–Meier analysis was used to represent progression‐free survival (PFS) and overall survival (OS). Univariable and multivariable Cox models were used to investigate prognostic factors. Results The analysis included 244 patients. The median OS was 8 months (95% confidence interval [CI]: 8–10) and the median PFS was 5 months (95% CI: 5–6). The univariable analysis showed that factors associated with shorter OS were older age ( p = 0.047), TNM stage 4 versus 3 ( p < 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 and 2 versus 0 ( p < 0.001), and >2 metastatic sites ( p = 0.004). Mediastinal radiotherapy (RT) ( p < 0.001), >1 irradiated site ( p = 0.026), 3 and 4 chemotherapy (CT) lines versus 1 ( p = 0.044 and 0.001, respectively), prophylactic cranial irradiation (PCI) ( p < 0.001), and surgery ( p = 0.001) correlated with longer OS. The multivariable analysis revealed statistically significant associations for TNM, ECOG PS 2 versus 0, number of CT lines, PCI, and surgery. A total of 23 patients (9.4%) survived ≥24 months, 39% of whom had received four CT lines and 48% had mediastinal RT. Conclusions Our data suggest that tumor burden, PS, and mediastinal RT strongly correlate with outcome. With the addition of immunotherapy to CT, the identification of new biomarkers as predictive factors is urgently required.

show abstract

Prognostic factor analysis of patients with small cell lung cancer: Real‐world data from 988 patients

Cited by 24 publications

References 20 publications

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer

Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer

PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients

Prognostic factors for survival in extensive‐stage small cell lung cancer: An Italian real‐world retrospective analysis of 244 patients treated over the last decade

Contact Info

Product

Resources

About